利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

69 条记录 (耗时 0.031 秒)

    TRANSSCLERAL DELIVERY
    1.
    发明申请
    TRANSSCLERAL DELIVERY 审中-公开
    TRANSSCLERAL交货

    公开(公告)号：US20120034279A1

    公开(公告)日：2012-02-09

    申请号：US13279179

    申请日：2011-10-21

    申请人： Eugene R. COOPER ,  David M. Kleinman ,  Thierry Nivaggioli ,  Philippe JM Dor ,  Sreenivasu Mudumba

    发明人： Eugene R. COOPER ,  David M. Kleinman ,  Thierry Nivaggioli ,  Philippe JM Dor ,  Sreenivasu Mudumba

    IPC分类号： A61K9/14 ,  A61P27/02 ,  A61K31/439

    CPC分类号： A61K9/0048 ,  A61K9/0019 ,  A61K31/436

    摘要： Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.

    摘要翻译： 通过将这些组织交叉施用治疗剂，可以有效地治疗与眼后段组织相关的疾病。 用于递送治疗剂使得它们穿过巩膜并到达这些组织的组合物，装置和方法包括在巩膜附近或在巩膜附近注射溶液或悬浮液，并植入包含与巩膜内或巩膜内的治疗剂的固体结构。 这些方法可用于施用雷帕霉素或相关化合物以治疗与年龄相关的黄斑变性相关的脉络膜新生血管形成。

    Transscleral delivery
    3.
    发明授权
    Transscleral delivery 有权
    跨收运

    公开(公告)号：US07585517B2

    公开(公告)日：2009-09-08

    申请号：US10945682

    申请日：2004-09-20

    申请人： Eugene R. Cooper ,  David M. Kleinman ,  Thierry Nivaggioli ,  Philippe J M Dor ,  Sreenivasu Mudumba

    发明人： Eugene R. Cooper ,  David M. Kleinman ,  Thierry Nivaggioli ,  Philippe J M Dor ,  Sreenivasu Mudumba

    IPC分类号： A61F2/00 ,  C12P21/04 ,  A61K38/00 ,  A61K31/44 ,  A61K31/445

    CPC分类号： A61K9/0048 ,  A61K9/0019 ,  A61K31/436

    摘要： Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.

    摘要翻译： 通过将这些组织交叉施用治疗剂，可以有效地治疗与眼后段组织相关的疾病。 用于递送治疗剂使得它们穿过巩膜并到达这些组织的组合物，装置和方法包括在巩膜附近或在巩膜附近注射溶液或悬浮液，并植入包含与巩膜内或巩膜内的治疗剂的固体结构。 这些方法可用于施用雷帕霉素或相关化合物以治疗与年龄相关的黄斑变性相关的脉络膜新生血管形成。

    TRANSSCLERAL DELIVERY
    6.
    发明申请
    TRANSSCLERAL DELIVERY 审中-公开
    TRANSSCLERAL交货

    公开(公告)号：US20090324690A1

    公开(公告)日：2009-12-31

    申请号：US12541866

    申请日：2009-08-14

    申请人： Eugene R. Cooper ,  David M. Kleinman ,  Thierry Nivaggioli ,  Philippe J. M. Dor ,  Sreenivasu Mudumba

    发明人： Eugene R. Cooper ,  David M. Kleinman ,  Thierry Nivaggioli ,  Philippe J. M. Dor ,  Sreenivasu Mudumba

    IPC分类号： A61K9/00 ,  A61K31/436 ,  A61P27/02

    CPC分类号： A61K9/0048 ,  A61K9/0019 ,  A61K31/436

    摘要： Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.

    摘要翻译： 通过将这些组织交叉施用治疗剂，可以有效地治疗与眼后段组织相关的疾病。 用于递送治疗剂使得它们穿过巩膜并到达这些组织的组合物，装置和方法包括在巩膜附近或在巩膜附近注射溶液或悬浮液，并植入包含与巩膜内或巩膜内的治疗剂的固体结构。 这些方法可用于施用雷帕霉素或相关化合物以治疗与年龄相关的黄斑变性相关的脉络膜新生血管形成。

    Drug delivery systems for treatment of diseases or conditions
    7.
    发明申请
    Drug delivery systems for treatment of diseases or conditions 审中-公开
    用于治疗疾病或病症的药物输送系统

    公开(公告)号：US20060257450A1

    公开(公告)日：2006-11-16

    申请号：US11386290

    申请日：2006-03-21

    申请人： Sreenivasu Mudumba ,  Philippe Jm Dor ,  Thierry Nivaggioli ,  David Weber ,  Sidiq Farooq

    发明人： Sreenivasu Mudumba ,  Philippe Jm Dor ,  Thierry Nivaggioli ,  David Weber ,  Sidiq Farooq

    IPC分类号： A61K31/4745 ,  A61F2/02

    CPC分类号： A61K9/0051 ,  A61K31/436 ,  A61K31/4745

    摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are solid drug delivery systems and methods for providing extended delivery of therapeutic agents to such tissues. A solid drug delivery system may be placed in a subject, including but not limited to placement between the sclera and the conjunctiva or transscleral placement. Described methods may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, age-related macular degeneration, or wet age-related macular degeneration in a subject. The solid drug delivery devices may comprise rapamycin or other therapeutic agents. Also described are methods of treating ocular diseases or disorders by administering an antiproliferative agent, including but not limited to rapamycin, proximal to an ocular device.

    摘要翻译： 包括但不限于眼睛中的组织的疾病和病症可被有效治疗，预防，抑制，发作延迟或由给予这些组织的治疗剂引起的回归。 本文描述的是用于向这些组织提供治疗剂的延长递送的固体药物递送系统和方法。 固体药物递送系统可以放置在受试者中，包括但不限于在巩膜和结膜之间的放置或经巩膜​​放置。 描述的方法可用于施用雷帕霉素以治疗或预防受试者的血管生成，脉络膜新生血管形成，年龄相关性黄斑变性或湿性年龄相关性黄斑变性。 固体药物递送装置可以包含雷帕霉素或其它治疗剂。 还描述了通过在近视眼装置上施用抗增生剂（包括但不限于雷帕霉素）来治疗眼部疾病或病症的方法。

    MTOR PATHWAY INHIBITORS FOR TREATING OCULAR DISORDERS
    9.
    发明申请
    MTOR PATHWAY INHIBITORS FOR TREATING OCULAR DISORDERS 审中-公开
    MTOR途径抑制剂治疗恶病质

    公开(公告)号：US20120114637A1

    公开(公告)日：2012-05-10

    申请号：US13265530

    申请日：2010-05-04

    申请人： Thierry Nivaggioli ,  David A. Weber ,  Philippe JM Dor ,  Philip Reilly

    发明人： Thierry Nivaggioli ,  David A. Weber ,  Philippe JM Dor ,  Philip Reilly

    IPC分类号： A61K31/436 ,  A61K31/12 ,  A61K31/192 ,  A61K31/5377 ,  A61K31/409 ,  A61K31/58 ,  A61K31/4545 ,  A61K31/675 ,  A61P27/02 ,  A61K39/395 ,  A61K31/4745 ,  A61K31/404

    CPC分类号： A61K31/573 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/436 ,  A61K31/506 ,  A61K31/519

    摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are ophthalmic formulations that deliver a variety of therapeutic agents, including but not limited to rapamycin (sirolimus), analogs thereof (rapalogs) or other mTOR inhibitors, to a subject for an extended period of time. The ophthalmic formulations may be placed in an aqueous medium of a subject, including but not limited to intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer a therapeutic agent to treat or prevent age-related macular degeneration, macular edema, diabetic retinopathy, uveitis, dry eye, or a hyperpermeability disease in a subject.

    摘要翻译： 包括但不限于眼睛中的组织的疾病和病症可被有效治疗，预防，抑制，发作延迟或由给予这些组织的治疗剂引起的回归。 本文描述的是眼科制剂，其向受试者递送多种治疗剂，包括但不限于雷帕霉素（西罗莫司），其类似物（rapalog）或其他mTOR抑制剂）延长时间。 眼用制剂可以放置在受试者的水性介质中，包括但不限于眼内或眼周内给药或靠近受试者待治疗的疾病或病症的部位放置。 可以使用一种治疗剂来治疗或预防受试者中年龄相关性黄斑变性，黄斑水肿，糖尿病性视网膜病变，葡萄膜炎，干眼症或高渗透性疾病的方法。

    Formulations for ocular treatment
    10.
    发明申请
    Formulations for ocular treatment 审中-公开
    眼部治疗剂型

    公开(公告)号：US20060182771A1

    公开(公告)日：2006-08-17

    申请号：US11351844

    申请日：2006-02-09

    申请人： Philippe Dor ,  Sreenivasu Mudumba ,  Thierry Nivaggioli ,  David Weber

    发明人： Philippe Dor ,  Sreenivasu Mudumba ,  Thierry Nivaggioli ,  David Weber

    IPC分类号： A61K31/4745 ,  A61K9/00

    CPC分类号： A61K9/0046 ,  A61K9/0019 ,  A61K9/0048 ,  A61K31/045 ,  A61K31/436 ,  A61K31/44 ,  A61K31/4745 ,  A61K47/10 ,  A61K47/12 ,  A61K47/44

    摘要： Diseases and conditions associated with tissues of the body, including tissues in the eye, can be effectively treated by administering therapeutic agents to those tissues. Described herein are self-emulsifying formulations and methods for delivering therapeutic agents to such tissues. A self-emulsifying formulation may be delivered to an aqueous medium of a subject, including but not limited to the vitreous. A method may, for instance, be used to administer rapamycin or related compounds to treat or prevent choroidal neovascularization associated with age-related macular degeneration, or to treat dry AMD. A self-emulsifying formulation may also be administered systemically, such as orally, to treat transplant rejection in a subject. A self-emulsifying formulation may comprise rapamycin, related compounds, or other therapeutic agents.

    摘要翻译： 可以通过向这些组织施用治疗剂来有效地治疗与身体组织（包括眼睛中的组织）相关的疾病和病症。 本文描述了将治疗剂递送到这种组织的自乳化制剂和方法。 自乳化制剂可以递送到受试者的水性介质，包括但不限于玻璃体。 例如，可以使用方法来施用雷帕霉素或相关化合物以治疗或预防与年龄相关性黄斑变性相关的脉络膜新血管形成，或治疗干性AMD。 自乳化制剂也可以全身施用，例如口服给药以治疗受试者的移植排斥。 自乳化制剂可以包含雷帕霉素，相关化合物或其它治疗剂。